Navigation Links
CareFusion Will Host An Earnings Conference Call on November 10, 2009 to Discuss the Results for the First Quarter of Fiscal 2010
Date:10/7/2009

SAN DIEGO, Oct. 7 /PRNewswire-FirstCall/ -- CareFusion Corporation (NYSE: CFN) today announced plans to release first quarter results for its fiscal 2010 on Tuesday, Nov. 10 following the close of trading on the New York Stock Exchange.

The company will host a webcast and conference call on Nov. 10 at 2:00 pm Pacific time (5:00 pm Eastern time) to discuss the results for its first quarter, ended on Sep. 30, 2009. To access the call and corresponding slide presentation, visit the investor page at carefusion.com or dial (866) 515-2914 within the U.S. or (617) 399-5128 from outside the U.S., and use the access code 87661284. A replay of the conference call will be available from 5:00 pm Pacific time (8:00 pm Eastern time) on November 10 through 8:59 pm Pacific time (11:59 pm Eastern time) on November 12 and can be accessed by dialing (888) 286-8010 in the U.S. or (617) 801-6888 Internationally and using the access code 93856981.

The Conference Call will also be Webcast live on the Internet. Investors and other interested parties may access the live webcast through the Investor Relations section, under Calendar of Events, on CareFusion's website at http://www.carefusion.com.

Log on at least 15 minutes before the call begins to register and download or install any necessary audio software.

About CareFusion Corporation

CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris(R) IV pumps, Pyxis(R) automated dispensing and patient identification systems, AVEA(R
'/>"/>

SOURCE CareFusion Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. CareFusion Earns Top Ranking in MD Buyline and KLAS Reports
2. BD Announces Live Webcast of Fourth Fiscal Quarter Earnings Conference Call
3. Medco Announces Date for Third-Quarter 2009 Financial Results; Company to Provide 2010 Earnings Guidance
4. Express Scripts Announces Third Quarter 2009 Earnings Conference Call
5. Spherix Reports First Quarter 2009 Earnings
6. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
7. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
8. Spherix Reports Second Quarter Earnings
9. NuVasive Announces Conference Call and Webcast of Third Quarter 2009 Results
10. Wound Management to Participate at Save A Leg, Save a Life Foundation National Conference
11. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Naurex Inc., a new clinical stage ... CNS disorders based on its novel GFPA NMDA ... a Phase I clinical trial of its lead ... subjects in the study. GLYX-13, a glycine ... the NMDA receptor, is initially being developed as ...
(Date:12/16/2009)... an inhalation drug delivery company, today announced that it ... financing round, exceeding the targeted total raise amount of ... Series A round will be utilized to continue the ... have the runway and resources to effectively demonstrate the ... Neville, CEO of Savara. ,, The company also ...
(Date:12/16/2009)... VIEW, Calif., Dec. 16 ChemoCentryx, Inc. ... in a Phase 2 clinical trial of CCX354, ... specifically target the CCR1 chemokine receptor for the ... is a highly potent and selective antagonist of ... of immune cells, such as monocytes and macrophages, ...
Breaking Medicine Technology:Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent 2ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 2ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 3ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 4ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 5Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 61871 1Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 61871 2Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 61871 3Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 61871 4U S Bishops Voice Disappointment in Abortion Funding Provisions in Senate Health Bill Urge Better Care for Immigrants and Affordability 61867 1U S Bishops Voice Disappointment in Abortion Funding Provisions in Senate Health Bill Urge Better Care for Immigrants and Affordability 61867 2Amaizing 3A Corn genome decoded 14937 1Amaizing 3A Corn genome decoded 14937 2Amaizing 3A Corn genome decoded 14937 3Amaizing 3A Corn genome decoded 14937 4
... Summary: Genmab,has completed recruitment of patients in the ... and cyclophosphamide to treat front line,CLL., Genmab ... recruitment of,56 patients in the Phase II study ... cyclophosphamide (FC) to treat chronic,lymphocytic leukemia (CLL) in ...
... July 9 Cerimon Pharmaceuticals,Inc., announced today ... study of,Simulect(R) (basiliximab) for the treatment of ... of the eye. The,randomized, double-masked, placebo-controlled study ... as maintenance therapy in 56 patients.,During the ...
Other Medicine Technology:Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study 2Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study 3Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis 2
(Date:12/16/2009)... Shoppers like knowing if their salad is from ... have found it burdensome to implement the recent ... to provide the information at point of sale. ... for easily making grocery and produce signs debuts ... retailers of unprocessed fruits, vegetables and other agricultural ...
(Date:12/16/2009)... New research published online, December 10, 2009 ... molecules present in pistachios, have anti-inflammatory properties. ... an inflammatory marker known as "Ifit-2" (INF-induced ... a complex biological response to harmful stimuli, ... underlies functional changes associated with many chronic ...
(Date:12/16/2009)... shrouded man found in a tomb on the edge of ... case of leprosy. Details of the research will be published ... The molecular investigation was undertaken by Prof. Mark Spigelman and ... for the Study of Infectious and Tropical Diseases at the ... Vernon of Lakehead University, Canada, Prof. Azriel Gorski of New ...
(Date:12/16/2009)... What happens when the families of sick and dying ... or for them? How do pediatricians respond to such ... religion and spirituality help some patients and families cope ... is almost always the families and patients who raise ... In the current issue of Southern Medical Journal ...
(Date:12/16/2009)... conducted through national AAD program ,, ... dies from melanoma, the deadliest form of skin ... successfully treated, if caught early. That,s why thousands ... cancer screenings in their communities through the American ... Program. The program recently reached a milestone - ...
Breaking Medicine News(10 mins):Health News:New Website Helps Grocers Comply With COOL Laws 2Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 2Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 3Health News:DNA of Jesus-era shrouded man in Jerusalem reveals earliest case of leprosy 2Health News:DNA of Jesus-era shrouded man in Jerusalem reveals earliest case of leprosy 3Health News:Prayer on the hospital floor 2Health News:Dermatologists Reach Skin Cancer Screening Milestone 2Health News:Dermatologists Reach Skin Cancer Screening Milestone 3
... Technology,Inc. (Nasdaq: ALGN ), the inventor of ... and brackets, announced today that,executives of Align Technology, ... Both presentations and breakout sessions, as noted ... Relations section of Align Technology,s website,at http://investor.aligntech.com ...
... CLEVELAND, Feb. 7 Cleveland-based risk consulting and,insurance ... will host,employee benefits experts from around the globe ... is part of the Oswald Seminar,Series., The ... Founder and Executive,Director of the National Center for ...
... 5 p.m.), SCOTTSDALE, Ariz., Feb. 7 , ... Dr. Lee Weinstein, a leading Arizona pediatric dentist in ... will be offering a Free Children,s Dental Day on ... The first 30 patients that call and schedule appointments will ...
... at the British Society for Computer Aided Orthopaedic Surgery ... saw graduates 95 per cent more confident using this ... training. , Professor Justin Cobb, Head of the ... conducted the trial on 32 undergraduate medical students at ...
... Research and the Management Sciences (INFORMS) today announced six ... Award for Achievement in Operations Research and the Management ... , Reflecting the wide-ranging use of operations research, ... from Western Europe, and two federal agencies. , The ...
... Together, Motherhood(R),Maternity and the March of Dimes(R) ... happy life. This year, the Motherhood Maternity Be ... to support healthy pregnancies,and healthy babies., (Photo: ... http://www.newscom.com/cgi-bin/prnh/20080207/NETH017-b ...
Other Medicine News:Health News:Align Technology Executives to Present at Upcoming Financial Conferences 2Health News:Experts Offer Global Benefits Strategies at Symposium 2Health News:Free Children's Dental Day; Expert Source on Children's Dental Health Available 2Health News:New training method for hip surgery 2Health News:New training method for hip surgery 3Health News:World's best analysts compete to win Edelman Prize in operations research and analytics 2Health News:Be Healthy Be Happy(TM) with the Motherhood(R) Maternity and March of Dimes(R) Bracelet 2
... The ImmunoDOT Borrelia (Lyme) ... (EIA) dot-blot test for the ... Both,species specific (anti-P39) and related ... and IgA) are detected in ...
The ImmunoWELL Borrelia (Lyme) Test is an enzyme immunoassay (EIA) for the qualitative and/or semiquantitative detection of Borrelia burgdorferi total antibodies (IgG, IgM, and IgA) in serum and is u...
The ImmunoWELL Thyroglobulin IgG Quantitative Test is a quantitative enzyme immunoassay (EIA) for screening and detection of autoantibodies against human thyroglobulin in serum and is used as an aid ...
... The ImmunoDOT Autoimmunity Screening Panel ... test for screening and detection of ... (ANA, DNA, SS-A/SS-B, RNP/Sm) in serum, ... in the diagnosis of systemic lupus ...
Medicine Products: